 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- || Keytruda (pembrolizumab) / Merck (MSD), MK-1248 / Merck (MSD)
Clinical, P1 data, Journal, Monotherapy: First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. (Pubmed Central) - Jun 9, 2021
P1
MK-1248 was generally well tolerated at doses up to 170 (monotherapy) and 60 mg (combination), with no DLTs or treatment-related deaths. Combination therapy provided limited antitumor responses.
- | Keytruda (pembrolizumab) / Merck (MSD), MK-1248 / Merck (MSD)
Trial completion, Enrollment change, Monotherapy, Metastases: Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) (clinicaltrials.gov) - Nov 15, 2018
P1, N=38, Completed, Sponsor: Merck Sharp & Dohme Corp.
Combination therapy provided limited antitumor responses. Active, not recruiting --> Completed | N=96 --> 38
- || Keytruda (pembrolizumab) / Merck (MSD), MK-1248 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) (clinicaltrials.gov) - Feb 5, 2018
P1, N=96, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | N=96 --> 38 Trial primary completion date: Mar 2019 --> Oct 2018 | Trial completion date: Mar 2019 --> Oct 2018
- || Keytruda (pembrolizumab) / Merck (MSD), MK-1248 / Merck (MSD)
Enrollment closed, Trial primary completion date, Monotherapy, Metastases: Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) (clinicaltrials.gov) - Apr 21, 2017
P1, N=96, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Mar 2019 --> Oct 2018 | Trial completion date: Mar 2019 --> Oct 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Mar 2019
- || Keytruda (pembrolizumab) / Merck (MSD), MK-1248 / Merck (MSD)
Trial primary completion date, Monotherapy, Metastases: Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) (clinicaltrials.gov) - Mar 10, 2017
P1, N=96, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Mar 2019 Trial primary completion date: Aug 2017 --> Nov 2017